The global biopharmaceutical excipients market size was valued at USD 2.1 billion in 2020 and is expected to reach USD 3.4 billion by 2028 expanding at a CAGR of 6.5% during the forecast period, 2021–2028. The growth of the market is attributed to continuous advancements in pharmaceutical manufacturing. The market is also driven due to an increase in the amount of protein therapeutics available, as well as the presence of a large number of excipients to protect these proteins from degradation.
Without a proper delivery mechanism, even the finest new therapeutic entity in the world is worthless. Tablets, capsules, oral liquids, topical creams and gels, transdermal patches, injectable medications, implants, eye products, nasal products, inhalers, and suppositories are among the various dose forms available today. Biopharmaceutical excipients are compounds that are used in pharmaceutical dosage forms to help with the manufacturing process, to protect, support, or increase stability, or to improve bioavailability or patient acceptability. It is also used to change the color, binding ability, taste, elegancy, and release rate of the active pharmaceutical ingredient depending on the need. Excipients are commonly used as binding agents, co-processed excipients, emulsifier agents, carrier agents, diluent excipients, and other stabilizing compounds.
Market Trends, Drivers, Restraints, and Opportunities
- Biopharmaceutical excipients are similar to biological compounds and provides higher efficacy and fewer side-effects are the factors which are projected to drive the market growth during the forecast period.
- Increasing emphasis on the rapid development of COVID-19 vaccines and therapeutic drugs is anticipated to boost the market growth in the coming years.
- Increasing development in pharmaceutical industry and increased R&D initiatives are estimated to fuel the market growth during the forecast period.
- Changing government trade policies all over the world present as major challenges that hinder the market in the coming years.
- High capital investments and time-intensive drug development process possess as key challenges that can hamper the market growth during the forecast period.
- Key players in the market are planning for expansion in emerging economies such as China and India are anticipated to offer lucrative opportunities for the market players.
Scope of the Report
The report on the global biopharmaceutical excipients market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Biopharmaceutical Excipients Market- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Products (Solubilizers & Surfactants/Emulsifiers [Triglycerides, Esters, and Others], Polyols [Mannitol, Sorbitol, and Others], Carbohydrates [Sucrose, Dextrose, Starch, and Others], and Specialty Excipients)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
IMCD; Colorcon; Clariant; BASF SE; Associated British Foods plc; Sigachi Industries Limited; Signet Excipients Pvt. Ltd (IMCD); Spectrum Chemical Manufacturing Corp.; Roquette Frères; J. RETTENMAIER & SÖHNE GmbH + Co KG; DFE Pharma; Evonik Industries AG; and Merck KGaA
Market Segment Insights
Carbohydrate segment is expected to account for a key share of the market
Based on products, the biopharmaceutical excipients market is segmented into solubilizers & surfactants/emulsifiers, polyols, carbohydrates, and specialty excipients. The solubilizers & surfactants/emulsifiers segment is further sub segmented into triglycerides, esters, and others. The polyols segment is further sub segmented into mannitol, sorbitol, and others. The carbohydrates segment is further segmented into sucrose, dextrose, starch, and others. The carbohydrate segment is expected to account for a key share of the market during the forecast period owing to increasing use of starch, sucrose, and dextrose in various drug manufacturing. Furthermore, the growing use of carbohydrates as bulking agents in the lyophilization of biomolecules like proteins is fueling market expansion.
On the other hand, the starch segment is anticipated to expand at a rapid pace during the forecast period owing to its increasing application in drug development. Because of its cost-effectiveness, inert nature, and great availability, starch is becoming more widely used. It can also be utilized as a binder, diluent, and disintegrant in a variety of non-prescription drugs, biopharmaceuticals, and food supplements.
Polyols segment is also expected to expand at a rapid pace during the forecast period owing to increasing protein therapeutics. Polyols are used to increase the tonicity and stability of protein formulations. Furthermore, it has been demonstrated to provide improved thermodynamic stability, which is critical for protein-based formulations.
North America is anticipated to dominate the market
On the basis of regions, the biopharmaceutical excipients market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to dominate the market at an impressive or healthy CAGR during the forecast period. The regional market growth can be attributed to presence of key players, increasing drug development, and a large population base.
On the other hand, Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to presence of large contract manufacturing organisations (CMOs) in drug development. China, India, and South Korea, for example, are heavily active in the development of biosimilars in this region. Affordability, a favorable regulatory framework, cost benefits, and the availability of a huge population base are all factors for the widespread development of biosimilars. Hence, biosimilar development requires the use of biopharmaceutical excipients to assure drug stability.
Segments Covered in the Report
The global biopharmaceutical excipients market has been segmented on the basis of
- Solubilizers & Surfactants/Emulsifiers
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- BASF SE
- Associated British Foods plc
- Sigachi Industries Limited
- Signet Excipients Pvt. Ltd (IMCD)
- Spectrum Chemical Manufacturing Corp.
- Roquette Frères
- J. RETTENMAIER & SÖHNE GmbH + Co KG
- DFE Pharma
- Evonik Industries AG
- Merck KGaA
Key players competing in the biopharmaceutical excipients market are IMCD; Colorcon; Clariant; BASF SE; Associated British Foods plc; Sigachi Industries Limited; Signet Excipients Pvt. Ltd (IMCD); Spectrum Chemical Manufacturing Corp.; Roquette Frères; J. RETTENMAIER & SÖHNE GmbH + Co KG; DFE Pharma; Evonik Industries AG; and Merck KGaA.
Companies in the market are developing new and advanced excipient solutions for supporting pharmaceutical drug development. In April 2020, DFE Pharma, for example, announced a new line of biopharmaceutical excipients for biologics stabilization. BioHale is a new excipient portfolio that includes the purest excipients available for use in formulations. It comprises of BioHale Sucrose and BioHale Trehalose, both of which are currently under development and will be sold online.
Business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase their market shares. For example, in February 2020, ReForm Biologics LLC and MilliporeSigma collaborated to commercialize the company's proprietary excipients utilized in biotherapeutic formulations. MilliporeSigma will support R&D and market ReForm Biologics' excipients for medication development under the terms of the collaboration.